Zimbabwe has declined a significant American health deal worth 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive information.
This rejection was revealed following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman has since explained that the US was requesting genetic material for research and commercial purposes while was not willing to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more negotiations to find a agreement suitable to all parties so the nation's vital HIV programme can continue.
Wider Implications
This rejection comes after a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US following concerns were filed about the safety of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to enhance openness and accountability.
According to reports, 16 nations in Africa have to date agreed to these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," he stated.
"Put simply, our country would provide the basic resources for medical research without any assurance that the end products would be accessible to our people should a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending structures already established via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its information, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how subsequent collaboration might be arranged in a manner that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body said it acknowledged the government's concerns, but suggested that negotiations should continue considering much of the country's Aids initiatives relied on external financing.
"Where technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it commented.
This impasse highlights the continuing challenges between accepting much-needed foreign assistance and protecting a country's data in an ever more data-driven world.